Royalty Pharma plc (RPRX) Guidance & Earnings Results

On 2026-08-05 Royalty Pharma plc raised guidance: "Portfolio Receipts guidance raised to $3,400M-$3,500M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RPRXRoyalty Pharma plcFollow RPRX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 36.7B
P/E TTM: 34.0
Dividend yield: 1.1%
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Raised	Portfolio Receipts guidance raised to $3,400M-$3,500M from $3,325M-$3,450M · full year
6 May 26	Raised	Portfolio Receipts guidance raised to $3,325M-$3,450M from $3,275M-$3,425M · full year
11 Feb 26	Raised	FY26 Portfolio Receipts $3,275-$3,425M vs FY25 $3,254M; Royalty Receipts growth 3-8% · full year
5 Nov 25	Raised	Portfolio Receipts $3.2B-$3.25B (previously $3.05B-$3.15B) · full year
6 Aug 25	Raised	FY25 Portfolio Receipts raised to $3,050-$3,150M from $2,975-$3,125M (growth 9%-12% from 6%-12%); Payments for operating costs improved to ~9%-9.5% of Portfolio Receipts from ~10%; Interest paid increased to $275M from $260M · full year

Royalty Pharma plc — questions

What guidance did Royalty Pharma plc give?: On 2026-08-05: "Portfolio Receipts guidance raised to $3,400M-$3,500M from $3,325M-$3,450M"
When does Royalty Pharma plc report earnings?: Royalty Pharma plc's next earnings report is expected on 2026-11-04.

Every figure on this page comes from Royalty Pharma plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.